Evidence map›Paper›PMID 39323315›Full record

Observational studyThe Laryngoscope2025

Sensorineural Hearing Loss in Patients With the m.1555A>G Mutation in the MTRNR1 Gene.

Jaime Gallo-Terán, Cristina Salomón-Felechosa, Rocío González-Aguado, Esther Onecha, Ana Fontalba, Ignacio Del Castillo, Carmelo Morales-Angulo

Abstract readObservational Study
In one paragraph

Observational study in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jaime Gallo-TeránDepartment of Radiology, Marqués de Valdecilla University Hospital, Santander, Spain.
Cristina Salomón-FelechosaDepartment of Anesthesiology, Marqués de Valdecilla University Hospital, Santander, Spain.
Rocío González-AguadoDepartment of Otolaryngology, Marqués de Valdecilla University Hospital, Santander, Spain.
Esther OnechaDepartment of Genetics, Marqués de Valdecilla University Hospital, Santander, Spain.
Ana FontalbaDepartment of Genetics, Marqués de Valdecilla University Hospital, Santander, Spain.
Ignacio Del CastilloServicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Carmelo Morales-AnguloHead of the Department of Otolaryngology and Head and Neck Surgery, Marqués de Valdecilla University Hospital, Santander, Spain.ORCID 0000-0002-4268-2762

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMutations in the MTRNR1 gene of mitochondrial DNA are associated with non-syndromic hearing loss and increased susceptibility to aminoglycoside ototoxicity. The aim of our study was to determine the clinical characteristics of sensorineural hearing loss caused by the m.1555A>G mutation in MTRNR1.

methodsAn observational retrospective study of the m.1555A>G mutation was conducted in patients with suspected hereditary bilateral sensorineural hearing loss in the Department of Otolaryngology of the Marqués de Valdecilla University Hospital (Cantabria, Spain) and in 100 controls with normal hearing.

resultsThe m.1555A>G mutation was found in 82 individuals from 20 different families and in none of the controls. Variable degrees of hearing loss were observed, ranging from normal hearing to profound deafness. Patients with a history of streptomycin administration exhibited significantly more pronounced hearing loss. The onset of hearing loss occurred from childhood to adulthood, with progression or stability over the years. No associated vestibular alterations or other clinical manifestations outside the ear were found. Two cochlear implant recipients showed significant improvement in speech comprehension.

conclusionsPatients with the m.1555A>G mutation in the MTRNR1 gene often develop bilateral, symmetric sensorineural hearing loss, predominantly affecting high frequencies, worsened by streptomycin administration. This mutation does not affect the vestibular function. The variability in the severity of hearing loss, the heterogeneity of phenotypic expression, and the presence of carrier individuals with normal hearing may indicate the existence of modifying factors, both environmental and genetic. Cochlear implantees showed a good response in terms of speech intelligibility. Genetic testing for this mutation is recommended in patients with a family history of hearing loss to prevent the use of aminoglycosides if the mutation is found. LEVEL OF EVIDENCE: 4 Laryngoscope, 135:901-907, 2025.

Indexed as

DNA, MitochondrialHearing Loss, SensorineuralAdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedMutationRetrospective StudiesYoung AdultDNA, Mitochondrialaminoglycosidesm.1555A>G mutationmitochondrial DNAsensorineural hearing loss

Identifiers

PMID39323315
PMCPMC11725701

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.